Robeco Institutional Asset Management B.V. - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 252 filers reported holding BIO-TECHNE CORP in Q1 2016. The put-call ratio across all filers is - and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
Robeco Institutional Asset Management B.V. ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$222,998
-70.2%
3,276
-64.3%
0.00%
-50.0%
Q2 2023$748,791
-34.9%
9,173
-40.8%
0.00%
-33.3%
Q1 2023$1,149,574
-6.7%
15,495
+4.3%
0.00%
-25.0%
Q4 2022$1,231,513
-61.2%
14,859
+32.9%
0.00%
-60.0%
Q3 2022$3,177,000
-59.4%
11,182
-50.4%
0.01%
-58.3%
Q2 2022$7,816,000
-10.0%
22,541
+12.5%
0.02%
+20.0%
Q1 2022$8,680,000
-36.6%
20,038
-24.3%
0.02%
-31.0%
Q4 2021$13,688,000
-39.4%
26,461
-43.2%
0.03%
-42.0%
Q3 2021$22,576,000
+49.8%
46,586
+39.2%
0.05%
+51.5%
Q2 2021$15,067,000
+68386.4%
33,463
+30884.3%
0.03%
Q2 2019$22,0000.0%1080.0%0.00%
Q1 2019$22,000
+37.5%
1080.0%0.00%
Q4 2018$16,000
-27.3%
1080.0%0.00%
Q3 2018$22,000
-99.4%
108
-99.6%
0.00%
-100.0%
Q2 2018$3,678,000
+19.8%
24,856
+22.3%
0.02%
+21.4%
Q1 2018$3,070,000
-38.0%
20,324
-63.1%
0.01%
-66.7%
Q4 2015$4,954,000
-10.9%
55,041
-8.5%
0.04%0.0%
Q3 2015$5,563,000
-6.1%
60,1710.0%0.04%
-6.7%
Q2 2015$5,925,000
-1.8%
60,1710.0%0.04%0.0%
Q1 2015$6,034,000
+7.9%
60,171
-0.6%
0.04%
+12.5%
Q4 2014$5,594,00060,5440.04%
Other shareholders
BIO-TECHNE CORP shareholders Q1 2016
NameSharesValueWeighting ↓
Ownership Capital B.V. 840,131$363,810,0004.80%
Montanaro Asset Management Ltd 89,950$38,952,0004.80%
Sandhill Capital Partners LLC 109,939$47,608,0004.09%
Brown Capital Management 918,328$397,673,0003.96%
STONE RUN CAPITAL, LLC 22,325$9,668,0003.57%
DF DENT & CO INC 686,484$297,275,0003.42%
Westwind Capital 27,741$12,013,0003.23%
MAIRS & POWER INC 657,962$284,924,0002.87%
Summit Creek Advisors LLC 58,133$25,174,0002.85%
Pembroke Management, LTD 76,250$33,019,0002.76%
View complete list of BIO-TECHNE CORP shareholders